1
|
Struga M, Roszkowski P, Bielenica A, Otto-Ślusarczyk D, Stępień K, Stefańska J, Zabost A, Augustynowicz-Kopeć E, Koliński M, Kmiecik S, Myslovska A, Wrzosek M. N-Acylated Ciprofloxacin Derivatives: Synthesis and In Vitro Biological Evaluation as Antibacterial and Anticancer Agents. ACS Omega 2023; 8:18663-18684. [PMID: 37273589 PMCID: PMC10233829 DOI: 10.1021/acsomega.3c00554] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Figures] [Subscribe] [Scholar Register] [Received: 01/27/2023] [Accepted: 05/09/2023] [Indexed: 06/06/2023]
Abstract
A novel series of N-acylated ciprofloxacin (CP) conjugates 1-21 were synthesized and screened as potential antimicrobial agents. Conjugates 1 and 2 were 1.25-10-fold more potent than CP toward all Staphylococci (minimal inhibitory concentration 0.05-0.4 μg/mL). Most of the chloro- (3-7), bromo- (8-11), and CF3-alkanoyl (14-16) derivatives expressed higher or comparable activity to CP against selected Gram-positive strains. A few CP analogues (5, 10, and 11) were also more effective toward the chosen clinical Gram-negative rods. Conjugates 5, 10, and 11 considerably influenced the phases of the bacterial growth cycle over 18 h. Additionally, compounds 2, 4-7, 9-12, and 21 exerted stronger tuberculostatic action against three Mycobacterium tuberculosis isolates than the first-line antitubercular drugs. Amides 1, 2, 5, 6, 10, and 11 targeted gyrase and topoisomerase IV at 2.7-10.0 μg/mL, which suggests a mechanism of antibacterial action related to CP. These findings were confirmed by molecular docking studies. In addition, compounds 3 and 15 showed high antiproliferative activities against prostate PC3 cells (IC50 2.02-4.8 μM), up to 6.5-2.75 stronger than cisplatin. They almost completely reduced the growth and proliferation rates in these cells, without a cytotoxic action against normal HaCaT cell lines. Furthermore, derivatives 3 and 21 induced apoptosis/necrosis in PC3 cells, probably by increasing the intracellular ROS amount, as well as they diminished the IL-6 level in tumor cells.
Collapse
Affiliation(s)
- Marta Struga
- Chair
and Department of Biochemistry, Medical
University of Warsaw, ul. Banacha 1, 02-097 Warsaw, Poland
| | - Piotr Roszkowski
- Faculty
of Chemistry, University of Warsaw, Pasteura 1, 02-093 Warsaw, Poland
| | - Anna Bielenica
- Chair
and Department of Biochemistry, Medical
University of Warsaw, ul. Banacha 1, 02-097 Warsaw, Poland
| | - Dagmara Otto-Ślusarczyk
- Chair
and Department of Biochemistry, Medical
University of Warsaw, ul. Banacha 1, 02-097 Warsaw, Poland
| | - Karolina Stępień
- Department
of Pharmaceutical Microbiology, Centre for Preclinical Research, Medical University of Warsaw, 02-097 Warsaw, Poland
| | - Joanna Stefańska
- Department
of Pharmaceutical Microbiology, Centre for Preclinical Research, Medical University of Warsaw, 02-097 Warsaw, Poland
| | - Anna Zabost
- Department
of Microbiology, National Tuberculosis and
Lung Diseases Research Institute, 01-138 Warsaw, Poland
| | - Ewa Augustynowicz-Kopeć
- Department
of Microbiology, National Tuberculosis and
Lung Diseases Research Institute, 01-138 Warsaw, Poland
| | - Michał Koliński
- Bioinformatics
Laboratory, Mossakowski Medical Research Institute, Polish Academy of Sciences, 5 Pawinskiego Street, 02-106 Warsaw, Poland
| | - Sebastian Kmiecik
- Biological
and Chemical Research Centre, Faculty of Chemistry, University of Warsaw, 02-089 Warsaw, Poland
| | - Alina Myslovska
- Faculty
of Chemistry, University of Warsaw, Pasteura 1, 02-093 Warsaw, Poland
| | - Małgorzata Wrzosek
- Department
of Biochemistry and Pharmacogenomics, Faculty of Pharmacy, Medical University of Warsaw, 02-097 Warsaw, Poland
| |
Collapse
|